Literature DB >> 1952869

In vitro susceptibility of Brucella melitensis to antibiotics.

E Rubinstein1, R Lang, B Shasha, B Hagar, L Diamanstein, G Joseph, M Anderson, K Harrison.   

Abstract

The in vitro susceptibilities of 86 recent clinical isolates of Brucella melitensis to minocycline, streptomycin, co-trimoxazole, rifampin, and six fluoroquinolones were determined. Minocycline exhibited the lowest MIC and was followed by rifampin and streptomycin. Among the quinolones, WIN 57273 and ciprofloxacin were the most active agents. No antibiotic combination of these agents exhibited synergy against 15 selected isolates. In killing rate experiments, streptomycin exhibited the most rapid kill (less than 12 h), while a complete kill with minocycline, rifampin, and ciprofloxacin was delayed up to 48 h. The combinations of streptomycin with each of minocycline, rifampin, or ciprofloxacin exhibited the fastest kills (within 2 h), while with the other combinations, a complete kill was delayed up to 96 h. These results demonstrate the discrepancy between the results of various in vitro methods in evaluating the antibiotic susceptibility of B. melitensis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952869      PMCID: PMC245295          DOI: 10.1128/AAC.35.9.1925

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks.

Authors:  J M Cisneros; P Viciana; J Colmenero; J Pachón; C Martinez; A Alarcón
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 2.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis.

Authors:  J Ariza; F Gudiol; R Pallarés; G Rufí; P Fernández-Viladrich
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

4.  In vitro susceptibility of Brucella to various antibiotics.

Authors:  W H Hall; R E Manion
Journal:  Appl Microbiol       Date:  1970-10

5.  Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.

Authors:  M Y Khan; M Dizon; F W Kiel
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Sensitivity of Brucella spp to tetracycline and its analogues.

Authors:  I D Farrell; P M Hinchliffe; L Robertson
Journal:  J Clin Pathol       Date:  1976-12       Impact factor: 3.411

7.  In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole.

Authors:  A Gutiérrez Altés; M Díez Enciso; P Peña García; A Campos Bueno
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

8.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

9.  Rifampin in the treatment of experimental brucellosis in mice and guinea pigs.

Authors:  A M Philippon; M G Plommet; A Kazmierczak; J L Marly; P A Nevot
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

10.  In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.

Authors:  J Bosch; J Liñares; M J López de Goicoechea; J Ariza; M C Cisnal; R Martin
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  20 in total

1.  Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis.

Authors:  D Gür; S Kocagöz; M Akova; S Unal
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 2.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 3.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Spontaneous peritonitis due to Brucella melitensis in a patient with cirrhosis.

Authors:  F Demirkan; H E Akalin; H Simşek; E Ozyilkan; H Telatar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

Review 5.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

Review 6.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

7.  Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.

Authors:  M Akova; O Uzun; H E Akalin; M Hayran; S Unal; D Gür
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin.

Authors:  B Shasha; R Lang; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.

Authors:  R Lang; B Shasha; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.